Picture of IRLAB Therapeutics AB logo

IRLAB A IRLAB Therapeutics AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m-33.75%
3m-0.5%
6m+64.86%
1yr+0.66%
Volume Change (%)
10d/3m-51.96%
Price vs... (%)
52w High-37.87%
50d MA-18.52%
200d MA+27.32%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-128.76%
Return on Equity-87.48%
Operating Margin-3183.6%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of IRLAB Therapeutics AB EPS forecast chart

Profile Summary

IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
May 13th, 2013
Public Since
February 28th, 2017
No. of Employees
37
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
51,868,406
Blurred out image of a map
Address
Arvid Wallgrens Backe 20, GOETEBORG, 413 46
Web
https://irlab.se/
Phone
+46 317573800
Contact
Tove Bergenholt
Auditors
Ohrlings PricewaterhouseCoopers AB

IRLAB A Share Price Performance

Upcoming Events for IRLAB A

Q1 2024 IRLAB Therapeutics AB Earnings Release

IRLAB Therapeutics AB Annual Shareholders Meeting

IRLAB Therapeutics AB Annual Shareholders Meeting

Q2 2024 IRLAB Therapeutics AB Earnings Release

Similar to IRLAB A

Picture of Biogaia AB logo

Biogaia AB

se flag iconOMX Nordic Exchange Stockholm

Picture of BoneSupport Holding AB logo

BoneSupport Holding AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Calliditas Therapeutics AB logo

Calliditas Therapeutics AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Camurus AB logo

Camurus AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Cline Scientific AB logo

Cline Scientific AB

se flag iconOMX Nordic Exchange Stockholm

FAQ